

## Associate Directors Meeting MINUTES

<b>MEETING DATE/TIME</b>	June 13, 2022 / 1:00 – 2:00 pm			
<b>EXECUTIVE OWNER</b>	Eileen White/Anita Kinney			
<b>EXECUTIVE NOTE TAKER</b>	Gina Londino-Greenberg			
<b>ATTENDEES</b>		Present		Present
	David August	X	Edmund Lattime	X
	<del>Adam Berger</del>		Zhiyuan Shen	X
	Andrew Evens	X	<del>Linda Tanzer</del>	
	Shridar Ganesan	X	Eileen White	X
	Howard Hochster	X	Gina Londino-Greenberg	X
	<del>Yibin Kang</del>		Biren Saraiya	X
	Anita Kinney	X	Tracie Saunders	X
	Haejin In	X		

<b>AGENDA TOPICS</b>		
<b>TOPIC</b>	<b>DISCUSSION/CONCLUSION</b>	<b>RECOMMENDATION /ACTION</b>
<b>Urgent Issues (Team)</b>	There was discussion around changing the name of the AD Meeting to Executive Committee, as that seems to be the trend with other NCI-Designated Cancer Centers. There was agreement about this name change and it will be the final recommendation to Dr. Libutti.	
<b>Deputy Director's Report (White)</b>	Recruitment of Basic Research faculty is occurring and several strong candidates have been identified.	
<b>Clinical Trial Accruals Updates/ Potential New Office of Translational Research (Hochster)</b>	<p>Please see attached presentation. It was noted that the figure on slide 5 needs to be revised to include more of the hospitals as several others (e.g., Jersey City Medical Center) have been conducting enrollments.</p> <p>Enrollments in clinical trials relating to prostate cancer (one of the catchment area priority cancers) are lower than expected, due to losing key clinical trialists in GU, such as I. Kim. It will be necessary to recruit new clinical research faculty to boost enrollments. The roll out of EPIC could also be slowing accrual numbers.</p> <p>There was discussion around needing a plan to address any shortfalls in clinical trials accruals. A Clinical Trialist in Breast Cancer needs to be recruited. M. Haigentz is working to open clinical trials in Lung, Head, and Neck throughout the network, but he is only able to do so much as the sole investigator. While Phase I leader S. Goel has started, there is still need for more Phase I physicians. Recruitment is likewise needed for Heme.</p> <p>There are currently 20 open oncologist positions and there is active recruitment occurring. It was noted that there is a national shortage of oncologists, especially clinical scholars. RWJBH had a major presence at this year's ASCO Conference, to promote recruitment. There was discussion around how Rutgers Cancer Institute can be more competitive. It was agreed that the ADs should communicate with contacts at other institutions to see if any colleagues may be seeking new opportunities. There are ongoing efforts to promote pay parity in order to retain current faculty. An IPA is expected to be put in place and approved by the faculty union. Pay disparities among clinicians is a Rutgers University-wide issue.</p> <p>There was agreement that clinical trials accruals across the network hospitals are good. There are also accruals now occurring at these network sites that otherwise would have occurred at Rutgers Cancer Institute in New Brunswick.</p>	H. Hochster will ask D. Toppmeyer for updates on the recruitments.

	<p>In discussing the possibility of creating a new Office of Translational Research, the recommendation was made that it be part of the Clinical Investigations and Precision Therapeutics (CIPT) CCSG Research Program, and that W. Arap and Rutgers Cancer Institute in Newark be engaged. The Precision Medicine Oncology (PMO) initiative has some of the same considerations listed in the presentation. A. Kinney noted that Population Science trials should still remain under the oversight of OHRS, as there is significant regulatory activity needed for any trial opened across the sites. It was noted how OHRS is very large already. However, the only other area that this new Office of Translational Research could fall is that of Research Administration. H. Hochster and L. Tanzer will discuss further to draft a proposal, that takes into account which office has the bandwidth and regulatory experience to run an Office of Translational Research. There was agreement that overall, it will be advisable to start this new office.</p> <p>There was discussion about how to best connect Population Science researchers with EPIC training. It was agreed that whichever regulatory office would cover Population Science trials would need to provide researchers with such education besides regulatory support.</p>	<p>Engagement of Basic and Population Science Researchers in the Disease Study Groups (DSGs) will be covered at a future meeting.</p>
	<p>Next Meeting July 11<sup>th</sup> at 1 PM</p>	